Journal article · 2026 · Open access
Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies
Journal of Medicinal Chemistry · Published 5 November 2026 · DOI 10.1021/acs.jmedchem.6c01475
In brief
“Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies” is a 2026 journal article by Léo Faïon and 22 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 1 citations as of 16 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at ChemRxiv.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 3.59
- References
- 46
- Authors
- 23
Abstract
Tuberculosis (TB) remains a major global health threat, intensified by rising drug resistance. Tricyclic spirolactam (TriSLa) inhibitors targeting mycobacterial type II NADH dehydrogenases (Ndh/NdhA) represent a promising antibiotic class but previously suffered from poor metabolic stability. Through extensive structure−activity and structure−property optimization, we identified BDM91465, a potent and metabolically stable TriSLa analog. Cryo-EM analysis revealed its binding mode within the menaquinone pocket of Ndh, consistent with observed SAR trends. BDM91465 displayed favorable pharmacokinetics, including good bioavailability and low clearance, resulting in sustained exposure above its MIC. In vivo, BDM91465 significantly reduced Mycobacterium tuberculosis burden in mice, mirroring the phenotype of Ndh-2 genetic inactivation. These findings provide the first demonstration of Ndh-2 inhibition efficacy in a murine model, validating Ndh-2 as a druggable target and supporting further development of TriSLa-based regimen.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Faïon, L., Ho, V. Q., Tangara, S., Liang, Y., Boarbi, S., Chatagnon, J., Djaout, K., Adnet, P., Kiass, M., Dam, S., Anoz‐Carbonell, E., Fischer, P., Vigier, C., Dumont, J., Eveque, M., Piveteau, C., Leroux, F., Deprez, B. P., Willand, N., . . . Villemagne, B. (2026). Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01475
MLA 9
Faïon, Léo, et al. “Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies.” Journal of Medicinal Chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.6c01475.
Chicago
Faïon, Léo, Vien QT Ho, Salia Tangara, Yingke Liang, Samira Boarbi, Jonathan Chatagnon, Kamel Djaout, et al. 2026. “Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies.” Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01475.
Harvard
Faïon, L. et al. (2026) ‘Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies’, Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.6c01475.
IEEE
L. Faïon et al., “Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies,” Journal of Medicinal Chemistry, 2026, doi: 10.1021/acs.jmedchem.6c01475.
BibTeX
@article{faion2026design,
title = {{Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies}},
author = {Faïon, Léo and Ho, Vien QT and Tangara, Salia and Liang, Yingke and Boarbi, Samira and Chatagnon, Jonathan and Djaout, Kamel and Adnet, Pierre‐Yves and Kiass, Mehdi and Dam, Sushovan and Anoz‐Carbonell, Ernesto and Fischer, Pauline and Vigier, Clément and Dumont, Julie and Eveque, Maxime and Piveteau, Catherine and Leroux, Florence and Deprez, Benoit P. and Willand, Nicolas and Rubinstein, John L. and Mathys, Vanessa and Hartkoorn, Ruben Christiaan and Villemagne, Baptiste},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01475},
url = {https://doi.org/10.1021/acs.jmedchem.6c01475}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Mycobacterium tuberculosis
- NDH-2
- ndhA
- metabolic stability
- structure-activity relationship
- tuberculosis drug resistance
- pharmacokinetics
- antitubercular agents
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Faïon, L., Ho, V. Q., Tangara, S., Liang, Y., Boarbi, S., Chatagnon, J., Djaout, K., Adnet, P., Kiass, M., Dam, S., Anoz‐Carbonell, E., Fischer, P., Vigier, C., Dumont, J., Eveque, M., Piveteau, C., Leroux, F., Deprez, B. P., Willand, N., . . . Villemagne, B. (2026). Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01475
How many times has this paper been cited?
1 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at ChemRxiv: sign in and open the PDF from this page.
Who wrote this paper?
Léo Faïon, Vien QT Ho, Salia Tangara, Yingke Liang, Samira Boarbi, Jonathan Chatagnon, Kamel Djaout, Pierre‐Yves Adnet, Mehdi Kiass, Sushovan Dam, Ernesto Anoz‐Carbonell, Pauline Fischer and 11 more.
What is the DOI of this paper?
10.1021/acs.jmedchem.6c01475, permanently at https://doi.org/10.1021/acs.jmedchem.6c01475. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.